Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Kenneth Joel Bloom"'
Publikováno v:
Journal of Clinical Oncology. 40:e13522-e13522
e13522 Background: Adequate reimbursement is considered a prerequisite for adoption of new diagnostic technologies that facilitate patient access to better treatments. Detailed longitudinal investigation of the adoption of new HCPCS codes and the fac
Autor:
Gowhar Shafi, Shivamurthy P.M., Anand Ulle, Krithika Srinivasan, Aravindan Vasudevan, Vikas Jadhav, Dr Sujit Joshi, Nirmal Vivek Raut, Jayant Khandare, Mohan Uttarwar, Kenneth Joel Bloom
Publikováno v:
Journal of Clinical Oncology. 40:3019-3019
3019 Background: Homologous recombination deficient (HRD) tumors are highly responsive to platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. Pathogenic BRCA-1 and BRCA-2 (BRCA1/2) alterations are key members of th
Autor:
Kenneth Joel Bloom, Dave Smart, Peter Riccelli, Raymond Henderson, Anthony M. Magliocco, Karina Hjort, Bob Holt, Karen Keating, Curtis A. Hanson, Wendy Moore
Publikováno v:
Blood
Introduction Measures taken to mitigate infection spread during the 2020 COVID-19 pandemic are considered to have caused significant unintended consequences on other diseases. Large decreases in the numbers of symptomatic and asymptomatic people pres
Autor:
Isabel Stacey, Jordan Clark, Kenneth Joel Bloom, Nital Patel, Enya Scanlon, Fotios Loupakis, Derry Mae Keeling, Wendy L. Allen
Publikováno v:
Journal of Clinical Oncology. 38:e15667-e15667
e15667 Background: KRAS G12C is a distinctively aggressive, poor survival, tumor genotype conferring resistance to anti-EGFR therapies in lung, colorectal (CRC) and pancreatic cancers. Prospective therapies targeting G12C have demonstrated promising
Publikováno v:
Journal of Clinical Oncology. 38:7528-7528
7528 Background: Acute Myeloid Leukemia (AML) is a devastating disease with poor overall survival. Access to precision medicines, is revolutionizing AML care and is driving an increase in Next Generation Sequencing (NGS) utilization to determine the
Publikováno v:
Journal of Clinical Oncology. 38:e15574-e15574
e15574 Background: The development and launch of first-generation tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib and entrectinib, has brought targeted treatment options to neurotrophic tropomyosin-related kinase (NTRK) fusion–p
Autor:
Peter Riccelli, Markus Eckstein, Kenneth Joel Bloom, Jordan Clark, Frank Policht, Derry Mae Keeling
Publikováno v:
Journal of Clinical Oncology. 38:e18052-e18052
e18052 Background: Homologous Recombination Repair (HRR) gene mutations result in Homologous Recombination Deficiency (HRD) associated with increased risk of high grade serous ovarian (HGOC) cancer and subsequent response to PARP inhibitors (PARPi).
Autor:
Mark Lawler, Dave Smart, Kenneth Joel Bloom, Jordan Clark, Raymond Henderson, Derek Hosty, Declan French
Publikováno v:
Journal of Clinical Oncology. 38:e13652-e13652
e13652 Background: Acute myeloid leukemia (AML) is a hematologic neoplasm with poor 5-year survival (33%; US 2016), a median survival of only 4 months for relapsed/refractory cases, and in 2016, a US incidence of 19,950 cases and 10,340 deaths. With
Autor:
Fernando Lopez-Rios, Frédérique Penault-Llorca, Andrew Wotherspoon, Keith Kerr, John W. Longshore, Julien Adam, Giuseppe Viale, Manfred Dietel, Noriko Motoi, John R Gosney, Ming-Sound Tsao, Birgit Guldhammer Skov, Kenneth Joel Bloom, Reinhard Büttner
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2017, 35 (34), pp.3867-3876. ⟨10.1200/JCO.2017.74.7642⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2017, 35 (34), pp.3867-3876. ⟨10.1200/JCO.2017.74.7642⟩
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non–small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 immunohistochemistry (IHC) testing. Nivol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::581a5be10ff02c7ebe6ca78db20239c6
https://hal.archives-ouvertes.fr/hal-01675259
https://hal.archives-ouvertes.fr/hal-01675259
Autor:
Yaron Turpaz, William H. Biggs, Eric Delwart, Kenneth Joel Bloom, Karen E. Nelson, Amalio Telenti, Chao Xie, Ahmed A. Moustafa, Ewen F. Kirkness, Emily H. M. Wong, J. Craig Venter
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 13, Iss 3, p e1006292 (2017)
PLoS Pathogens, Vol 13, Iss 3, p e1006292 (2017)
The characterization of the blood virome is important for the safety of blood-derived transfusion products, and for the identification of emerging pathogens. We explored non-human sequence data from whole-genome sequencing of blood from 8,240 individ